RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Sinphar Pharmaceutical Co Equity 2024

Sinphar Pharmaceutical Co Equity

3.1 B TWD

Sinphar Pharmaceutical Co Dividend yield

2.74 %

Ticker

1734.TW

ISIN

TW0001734002

In 2024, Sinphar Pharmaceutical Co's equity was 3.1 B TWD, a 5.74% increase from the 2.93 B TWD equity in the previous year.

Sinphar Pharmaceutical Co Aktienanalyse

What does Sinphar Pharmaceutical Co do?

Sinphar Pharmaceutical Co Ltd is a Taiwanese company specializing in the pharmaceutical industry, founded in 1970. It is a leading manufacturer of pharmaceuticals and specializes in the production of generics and branded drugs. The company is headquartered in Taipei, Taiwan and has become an important player in the global pharmaceutical market in recent years. It has several divisions specializing in the production of drugs, supplements, and medical devices. Sinphar has two main business models, including the development of its own products and the licensing of products from other companies. The company has its own manufacturing facility, certified to FDA and GMP (Good Manufacturing Practice) standards, allowing it to produce high-quality drugs. Sinphar offers a wide range of products, including pharmaceuticals, supplements, medical devices, and other health products. It also has a variety of products focusing on the treatment of diseases such as diabetes, cancer, heart disease, and other conditions. The company has several divisions specializing in the development of drugs and medical devices. It also has an extensive research and development department focusing on the development of new drugs and medical devices. Sinphar works closely with various academic institutions and research institutes to stay updated on the latest developments in medicine and utilize the latest technologies. The company has several subsidiaries, including ones in the USA, China, and Singapore. Through these subsidiaries, the company has access to various local markets and can sell its products worldwide. Sinphar has received several awards and recognition for its work in recent years. In 2019, the company was awarded by the Taiwanese Ministry of Education for its exceptional performance in the development of medical devices and pharmaceutical products. Overall, Sinphar Pharmaceutical Co Ltd is a leading player in the pharmaceutical industry with a long history of developing high-quality drugs and medical devices. It specializes in the production of generics and branded drugs and has several divisions specializing in the development of drugs and medical devices. With its subsidiaries and research and development department, the company is well positioned to continue growing and evolving in the future. Sinphar Pharmaceutical Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Sinphar Pharmaceutical Co's Equity

Sinphar Pharmaceutical Co's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Sinphar Pharmaceutical Co's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Sinphar Pharmaceutical Co's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Sinphar Pharmaceutical Co's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Sinphar Pharmaceutical Co’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Sinphar Pharmaceutical Co Stock

What is the equity of Sinphar Pharmaceutical Co this year?

Sinphar Pharmaceutical Co has equity of 3.1 B TWD this year.

What was the equity of Sinphar Pharmaceutical Co compared to the previous year?

The equity of Sinphar Pharmaceutical Co has increased/decreased by 5.74% increased compared to the previous year.

What impact does a high equity have on investors of Sinphar Pharmaceutical Co?

A high equity is advantageous for investors of Sinphar Pharmaceutical Co as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Sinphar Pharmaceutical Co?

A low equity can be a risk for investors of Sinphar Pharmaceutical Co, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Sinphar Pharmaceutical Co affect the company?

An increase in equity of Sinphar Pharmaceutical Co can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Sinphar Pharmaceutical Co affect the company?

A reduction in equity of Sinphar Pharmaceutical Co can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Sinphar Pharmaceutical Co?

Some factors that can affect the equity of Sinphar Pharmaceutical Co include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Sinphar Pharmaceutical Co so important for investors?

The equity of Sinphar Pharmaceutical Co is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Sinphar Pharmaceutical Co take to change the equity?

To change equity, Sinphar Pharmaceutical Co can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Sinphar Pharmaceutical Co pay?

Over the past 12 months, Sinphar Pharmaceutical Co paid a dividend of 1 TWD . This corresponds to a dividend yield of about 2.74 %. For the coming 12 months, Sinphar Pharmaceutical Co is expected to pay a dividend of 1 TWD.

What is the dividend yield of Sinphar Pharmaceutical Co?

The current dividend yield of Sinphar Pharmaceutical Co is 2.74 %.

When does Sinphar Pharmaceutical Co pay dividends?

Sinphar Pharmaceutical Co pays a quarterly dividend. This is distributed in the months of August, September, August, August.

How secure is the dividend of Sinphar Pharmaceutical Co?

Sinphar Pharmaceutical Co paid dividends every year for the past 20 years.

What is the dividend of Sinphar Pharmaceutical Co?

For the upcoming 12 months, dividends amounting to 1 TWD are expected. This corresponds to a dividend yield of 2.74 %.

In which sector is Sinphar Pharmaceutical Co located?

Sinphar Pharmaceutical Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Sinphar Pharmaceutical Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Sinphar Pharmaceutical Co from 8/18/2023 amounting to 1 TWD, you needed to have the stock in your portfolio before the ex-date on 7/13/2023.

When did Sinphar Pharmaceutical Co pay the last dividend?

The last dividend was paid out on 8/18/2023.

What was the dividend of Sinphar Pharmaceutical Co in the year 2023?

In the year 2023, Sinphar Pharmaceutical Co distributed 0.2 TWD as dividends.

In which currency does Sinphar Pharmaceutical Co pay out the dividend?

The dividends of Sinphar Pharmaceutical Co are distributed in TWD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Sinphar Pharmaceutical Co

Our stock analysis for Sinphar Pharmaceutical Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Sinphar Pharmaceutical Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.